Scientific Programme

WS: Molecular Genectics of Lung Cancer - Principles and Applications
Chair: Marileila Varella-Garcia, USA

PL1: Plenary Session I - Advances in NSCLC Treatment
Chairs: Eduardo Richardet, Argentina & Mario Varangot, Uruguay

• PL1.1: Overview of Personalized Medicine - Paul Bunn, USA
• PL1.2: Selection of the Scheme of Chemotherapy in 1st Line in Advanced NSCLC - David Gandara, USA
• PL1.3: Lung Cancer and the Immunological System - Nise Yamaguchi, Brazil

PL1.4: Discussant: Nise Yamaguchi, Brazil

PL2: Plenary Session II - Breakthrough Knowledge in The Lung Cancer Arena
Chairs: Pedro Kasdorf, Uruguay & Adrian Hannois, Argentina

• PL2.1: Updates in Lung Cancer Stem Cell Research - Claudio Dansky-Ullmann, USA
• PL2.2: Relevant Pathways in Lung Cancer - Understanding Prognostic and Predictive Factors - Marileila Varella-Garcia, USA
• PL2.3: Molecular Pathogenesis of Lung Cancer in Never Smokers - Ignacio Wistuba, USA

PL2.4: Discussant: Lydia Puricelli, Argentina

Lunch Break & Poster Session (author stand by time)
** Posters are displayed from 09:00 - 18:00 in Room Catalinas, authors will stand by their poster from 13:00 - 15:00 to answer questions from delegates

13:30 - 14:30

Boehringer Ingelheim Symposium: "The Dawn of Tailored Treatment in NSCLC" (Lunch provided)
Chair: Carlos Silva, Argentina

• Introduction & Welcome - Carlos Silva, Argentina
• Understanding the Reasons Behind Resistance to First-Generation Tyrosine Kinase Inhibitors: Mechanisms and Therapeutic Options - Vera Hirsh, Canada
• ErbB Family Mutations in NSCLC: How EGFR and HER2 Mutation Testing is Changing the Way We Make Treatment Decisions - Noemi Reguart, Spain
• Latest Developments in Angiokinase Inhibition in NSCLC: Targeting the Right Pathways with the Right Agents - John Heymach, USA
• Debate

GS1: Bridging the Gap Between Specialties in Lung Cancer Treatment
Chairs: Ricardo Beyruti, Brazil & Nestor Spizzamiglio, Argentina

• GS1.1: Diagnostic Procedures in Lung Cancer - James Jett, USA
• GS1.2: The New Staging System - Harvey Pass, USA
• GS1.3: Recent Technological Advances in Radiation Therapy for Lung Cancer - Hak Choy, USA
• GS1.4: Interactions Among Asbestos and Erlonite with Genetic Predisposition and Viral Infection Facilitate the Development of Malignant Mesothelioma - Michele Carbone, USA

GS1.5: Discussant: Berta Roth, Argentina

Round Table Discussions

Topics:

1. NSCLC - Neo-Adjuvant Treatment - Expert: Rafael Rosell, Spain / Chair: Martin Richardet, Argentina
2. Stage II Treatment - Expert: David Gandara, USA / Chair Gonzalo Recondo, Argentina
3. Advanced NSCLC Chemotherapy First Line - Expert: Chandra Belani, USA / Chair: Ricardo Kirchuk, Argentina
4. NSCLC Maintenance Therapy - Expert: Giorgio Scagliotti, Italy / Chair: Norma Pilnik, Argentina
5. SCLC Treatment - Expert: Vera Hirsh, Canada / Chair: Luis Fein, Argentina
6. Staging - Expert: Paul Bunn, USA / Chair: Zenon Beguelin, Argentina

GS2: From The Bench to The Bed Side
Chairs: Miriam Losanovscky, Argentina & Elisa Bal, Argentina

• GS2.1: Cancer Microenviroment: The Role of Stroma in Non-Small Cell Lung Cancer - Noemi Reguart, Spain
• GS2.2: Role of Molecular Pathology in the Personalized Treatment of Lung Cancer - Ignacio Wistuba, USA
• GS2.3: Face I Trial in Lung Cancer - Adrian Senderowicz, USA

GS2.4: Discussant: Claudio Dansky-Ullmann, USA

GS3: Personalized Medicine
Chairs: Eduardo Richardet, Argentina & Jorge Madrid, Chile

• GS3.1: Applied Pharmacogenomics to The Tailored Use of Chemotherapy and Molecular Drugs - Rafael Rosell, Spain
• GS3.2: Individualized Medicine: Challenges in Regulatory Issues for Drug Development and Reimbursement - David Gandara, USA

GS3.3: Discussant: Norma Pilnik, Argentina

O: Proffered Paper (Oral Abstract) Session
Chairs: Marileila Varella-Garcia, USA &

• O.1: Vorinostat in Patients With Advanced Malignant Pleural Mesothelioma (MPM) who Have Failed Prior Pemetrexed and Either Cisplatin or Carboplatin Therapy: A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial – Hedy Kindler, USA
• O.2: New prognostic biomarkers in Stage I and II non-small lung cancer (NSCLC) – Maria Carlini, Argentina
• O.3: MAGRIT Phase III trial of MAGE-A3 ASCI (Antigen Specific Cancer Immunotherapeutic) as adjuvant treatment in stage IB to IIIA NSCLC patients: MAGE-A3 gene expression frequency and baseline demographics – Carlos Barrios, Brazil
• O.4: Axitinib with or without dose interruption in combination with cisplatin and pemetrexed for treatment of non-squamous non–small cell lung cancer – Chandra Belani, USA - not presented due to flight delay
• O.5: A Phase II study of BIBW 2992 in patients with adenocarcinoma of the lung and activating EGFR mutations (LUX-Lung 2) – Chih Hsin Yang, Taiwan
• O.6: The role of Stable Disease (SD), Disease Control Rate (DCR) and Progression Free Survival (PFS) as Surrogate Endpoints of Overall Survival (OS) in Advanced Non-Small Cell Lung Cancer (NSCLC) – Ina Nordman, Australia
• Discussion / Q + A

PD: Poster Discussion Session
Chairs: Claudio Martin, Argentina & Diego Touya, Uruguay

PD.2-4: Discussant: Ignacio Wistuba, USA

• PD.2: Thymidylate synthase polymorphisms and immunohistochemistry in non-small cell lung cancer – Jan Stoehlmacher, Germany
• PD.3: Frequency of Adenocarcinoma Histological Pattern in patients with Non Small Cell Lung Cancer (NSCLC) – Claudia Bagnes, Argentina
• PD.4: Comprehensive Analysis of DNA Repair Gene Polymorphisms and Survival in Patients with Early Stage Non-Small Cell Lung Cancer – Seung Soo Yoo, Korea

PD.5-6: Discussant: Fred Hirsch, USA

• PD.6: Influence of CXCR4 Expression by Immunohistochemistry (IHC) on Outcome in Metastatic NSCLC – Gwyn Bebb, Canada

PD.8-9: Discussant: Giorgio Scagliotti, Italy

• PD.8: Clinical activity of BIBW 2992, an irreversible inhibitor of EGFR/HER1 and HER2 in adenocarcinoma of the lung with mutations in the kinase domain of HER2neu – Susana Concalves, Argentina
• PD.9: A Phase II double-blind study to investigate efficacy and safety of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small cell lung cancer (NSCLC) – Claudia Gann, Germany

PD3: Plenary Session III - IASLC/ASCO Joint Symposium
Chairs: Lucia Delgado, Uruguay & TBC

• PL3.1: Histology Based Approach in The Systemic Treatment of NSCLC - Giorgio Scagliotti, Italy
• PL3.2: Adjuvant and Neoadjuvant Treatment of Resectable Lung Cancer - Rafael Rosell, Spain
• PL3.3: Biomarkers and Drug Development - Fred Hirsch, USA

PL3.4: Discussant: Claudia Bagnes, Argentina

PL4: Plenary Session IV - Multidisciplinary Treatment in NSCLC
Chairs: Guadalupe Pallota, Argentina & Mauro Zamboni, Brazil

• PL4.1: Treatment of Bone Metastases in NSCLC - Vera Hirsh, Canada
• PL4.2: Controversies in the Surgical Management of Early Stage NSCLC - Harvey Pass, USA
• PL4.3: Role of PCI in Small and Non Small Cell Lung Cancer - Hak Choy, USA

PL4.4: Discussant: Riad Younes, Brazil

Lunch Break & Poster Session
** Posters are displayed from 09:00 - 18:00 in Room Catalinas, authors will stand by their poster from 13:00 - 15:00 to answer questions from delegates

Merck Symposium: Erbitux treatment in lung cancer. Targeting patients (Lunch provided)
Chair: Claudio Martin, Argentina

• Introduction - Claudio Martin, Argentina

• Erbitux Treatment in 1st Line NSCLC. Choosing the Patients - Rosario García Campelo, Spain

• Clinical Experience - Carlos Henrique Barrios, Brazil

• Conclusions. Final remarks - Claudio Martin, Argentina

GS4: Translational Research in Lung Cancer
Chairs: Elias Hurtado Hoyo, Argentina & Gabriel Krygier, Uruguay

• GS4.1: What's New in Translational Research for Lung Cancer? - John Heymach, USA
• GS4.2: 2nd Line Therapies - Chandra Belani, USA
• GS4.4: Innovative Treatments in Lung Cancer Research - Rogerio Lilenbaum, USA

GS4.5: Discussant: Gonzalo Recondo, Argentina

Round Table Discussions

Topics:

1. Surgery: Initial and Advanced Stages - Expert: James Jett + Harvey Pass, USA / Chair: Abel Gilardon, Argentina
2. Radiotherapy: Initial and Advanced Stages - Expert: Hak Choy, USA / Chair: Maria Fernanda Vazques, Argentina
3. NSCLC Adjuvant Treatment - Expert: Paul Bunn, USA / Chair: Florencia Perazzo, Argentina
4. Advanced NSCLC - 2nd Line - Expert: Noemi Reguart, Spain / Chair: Claudio Martin, Argentina
5. Mesothelioma - Expert: Michele Carbone, USA / Chair: Claudia Bagnes, Argentina
6. Toxicity of New Drugs - Expert: Fred Hirsch, USA / Chair: Diego Kaen, Spain

GS5: Main Barriers to Clinical Research in Latin America (FLASCA Perspective)
Chairs: Lucia Delgado, Uruguay & Guadalupe Pallota, Argentina

• GS5.1: Clinical Trials and Published Studies from Latin America - Lucia Delgado, Uruguay
• GS5.2: Funding for Academic Research - Lucia Delgado, Uruguay; Guadalupe Pallota, Argentina; Nise Yamaguchi, Brazil
• GS5.3: Regulatory Framework - Rodrigo Fresco, Uruguay
• Discussion: Eduardo Cazap, Argentina; Nise Yamaguchi, Brazil; Eduardo Richardet, Argentina; Gacriela Sabini, Uruguay; Ignacio Muse, Uruguay

GS6: New Frontiers in Lung Cancer Research
Chairs: Marisa Fazzino, Uruguay & Luis Fein, Argentina

• GS6.1: Learning From The Past: Where Should We Go From Now? - Giorgio Scagliotti, Italy
• GS6.2: Combination of Drugs Inhibiting Multiple Signaling Pathways in NSCLC - Paul Bunn, USA

GS6.3: Discussant: Jorge Gallardo, Chile

GS7: Closing Ceremony
Chairs: Paul Bunn, USA; David Gandara, USA; Eduardo Richardet, Argentina; Mario Varangot, Uruguay; Nise Yamaguchi, Brazil; Marileila Varella-Garcia, USA; Guadalupe Pallotta, Argentina

• GS7.1: Summary/Discussion of Top 3 Abstracts - Guadalupe Pallotta, Argentina
• GS7.2: Summary of Round Table Discussions - Mario Varangot, Uruguay
• GS7.3: Closing Remark: A Step Forward - Latin American Consensus - Eduardo Richardet, Argentina & Nise Yamaguchi, Brazil